AI’s ROI: Cutting Billions from Cardiovascular Costs

The spiraling cost of cardiovascular care is a massive problem for healthcare systems everywhere, and everyone’s looking for real solutions that deliver an economic return. As investors pour money into the AI healthcare market, they’re rightfully asking a tough question: which of these AI applications actually cut cardiovascular care costs, and how do their business models stack up when it comes to measurable ROI? Finding the answer means digging past the slick demos and demanding rigorous, independent verification of vendor claims using solid economic frameworks.

Working through the Field: Precision Medicine vs. Acute Intervention

When you look at AI for cardiovascular cost-cutting, it basically splits into two camps, each with different ways of making economic sense. On one side are precision medicine platforms like Tempus AI, which focus on optimizing treatment paths with advanced diagnostics. Tempus AI, with its $12.42 billion market cap and backing from GV, uses genomic testing to personalize cancer care. The idea, when applied to heart disease, is to preempt major health events and fine-tune therapies for the best results. The thinking is, if you can spot genetic risks or specific disease markers early on, clinicians can step in sooner and more effectively, which should reduce the need for expensive, heavy-duty interventions later. The problem is that the direct cost savings from broad genomic testing are still fuzzy, since the metrics are often just the cost of the test itself plus any changes in treatment. Tempus AI SEC filings on clinical utility data Then you have companies like Viz.ai, which is all about acute intervention. After a $100 million Series D round and with a $1.2 billion valuation (thanks to investors like Tiger Global), Viz.ai is focused on the here and now. Its AI-powered platform is designed for stroke triage, speeding up the detection and treatment of large vessel occlusion (LVO) strokes. Its platform spots these strokes on scans, gets the right care teams moving faster, and cuts the time to treatment. This directly improves patient outcomes and, importantly, slashes the long-term costs of disability and long hospital stays. The business model is usually a per-patient subscription, and the ROI comes from things you can actually measure: shorter inpatient stays, better functional outcomes, and less need for rehab. The economic argument here is much more direct and can be quantified almost immediately, showing a clear drop in resource use during a crisis. In fact, peer-reviewed economic analyses of AI-guided stroke care are starting to back up these savings, showing a real potential to dent overall care spending.

The Pitfalls of Automation: Lessons from Olive AI

But let’s be clear, not every AI healthcare venture strikes gold. Some just burn through cash. Olive AI is the cautionary tale everyone’s talking about. After raising a staggering $902 million from investors including Tiger Global, Olive AI set out to slash operational costs by automating administrative work. The idea was simple enough: automate repetitive back-office work like claims processing and prior authorizations to free up staff and cut overhead. But despite the massive investment, Olive AI completely shut down. It’s a hard lesson in the need to look past the sales pitch and at the real economic impact. Olive’s flameout proves that while administrative mess is a huge cost driver in healthcare, actually getting a positive ROI from an AI solution is way more complicated than it looks. You have to rigorously check if those “operational cost savings” are real on a system level, or if you’re just automating one small task while creating new problems elsewhere (a classic implementation trap). This whole disaster just hammers home why you need independent verification of a vendor’s claims, especially when the promised savings are indirect and depend on complex workflow changes that might never happen.

An Investor Framework for Evaluating Cardiovascular AI Business Models

So how does an investor sort through the marketing fluff to find the real money in cardiovascular AI? You need a framework that looks at actual business models and verifiable outcomes. Our framework focuses on three main types and what drives their ROI: 1. Precision Medicine Platforms (e.g., Tempus AI):

• Model: It’s often a mix of service fees (for the genomic tests) and maybe some value-based contracts down the line.
• ROI Driver: The ROI is supposed to come from preventing expensive problems down the road through earlier diagnosis and targeted therapies. The hard part is proving the AI was directly responsible for the savings, especially when you’re looking at a 1-3 year timeline.
• Key Metric: You need to measure the total cost of care for a patient group over 1-3 years and compare it to a control group, focusing on hard numbers like inpatient admissions, emergency room visits, and how many procedures were done. 2. Acute Intervention Tools (e.g., Viz.ai):
• Model: Usually a SaaS subscription or a fee for each patient analyzed.
• ROI Driver: Here, the savings are direct and fast. You’re improving efficiency in a crisis, which means shorter hospital stays, fewer complications, and lower long-term rehab and chronic care costs.
• Key Metric: Look for lower length of stay, fewer readmissions for specific conditions, and better functional independence scores that translate to lower post-acute spending. It’s much easier to quantify this stuff in the short term. 3. Administrative Automation (e.g., Olive AI’s former model):
• Model: A SaaS subscription, typically based on how many transactions are processed or how many full-time employees are supposedly saved.
• ROI Driver: This is all about efficiency: cutting labor costs, getting paid faster, and reducing claim denials.
• Key Metric: Direct cuts in labor costs, a faster revenue cycle, and fewer denied claims. But as Olive AI showed, the real challenge is making sure these savings actually give you a net positive ROI once you account for the cost and pain of implementation. For a great example of proven ROI in managing cardiovascular care, look at Hello Heart. Their peer-reviewed data shows a solid $1,800 per-member savings and a 47% drop in inpatient admissions for people managing hypertension and heart disease Peer-reviewed study on Hello Heart ROI. It’s proof that you can get huge cost reductions when an AI tool actually changes patient behavior and prevents expensive hospital visits in the first place.
  

  Methodology Note on Comparative Metrics

  You can’t compare these different AI models without a consistent way to measure ROI. At Healthcare AI ROI Research, our method is all about independent verification. We don’t just take vendor case studies at face value. We run everything by expert panels of health economists, doctors, and payers. That’s the only way to really pick apart the assumptions, check the data quality, and see if the claimed savings would actually apply elsewhere. We’re looking for metrics that tie the AI directly to a drop in total cost of care. Think per-member-per-month (PMPM) savings, fewer expensive events like hospital stays or ER visits, and even improvements in quality-adjusted life years (QALYs) that have a dollar value. We also dig into the reimbursement side of things, is there an established CPT code for this? Could it get NTAP eligibility? A clear path to getting paid is a huge factor for commercial viability and scaling the ROI. We use CMS Innovation Center reports and other health economic studies as our benchmarks for what’s credible. In the end, any decision to put capital into cardiovascular AI has to be based on cold, hard data that shows a real, verifiable cost reduction, not just a perceived one. The massive gap between companies with peer-reviewed successes and ventures that just burn out shows why investors have to demand total transparency and independent validation. Anything less is just a gamble.